Inspiratory Muscle Training in Nemaline Myopathy
NEMTRAIN
1 other identifier
interventional
42
1 country
1
Brief Summary
Nemaline myopathy is a rare congenital myopathy. Respiratory failure is the main cause of death in these patients. The primary objective of this study is to determine the effect of a 8-week inspiratory muscle training program on respiratory muscle function in nemaline myopathy patients. The secondary objective is to determine respiratory muscle function in nemaline myopathy patients and its correlation with clinical severity and general neuromuscular function. The nemaline myopathy patients will be included in the first phase for a clinical characterization. From this phase patients will be selected for the second phase, which is a controlled before-after trial of inspiratory muscle training. The primary outcome is the change in maximal inspiratory pressure (MIP) after active inspiratory muscle training
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Oct 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 10, 2018
CompletedFirst Submitted
Initial submission to the registry
October 15, 2018
CompletedFirst Posted
Study publicly available on registry
November 2, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 25, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 25, 2021
CompletedDecember 5, 2024
March 1, 2021
2.5 years
October 15, 2018
December 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Change of maximal inspiratory pressure (cmH2O)
Obtained with handheld device
Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Secondary Outcomes (20)
Change of diaphragm thickness (mm)
Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of diaphragm thickening (ratio)
Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of diaphragm excursion (cm)
Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of peak cough flow (L/s)
Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
Change of forced vital capacity (% predicted)
Baseline, after 8 weeks sham IMT, after 8 weeks active IMT
- +15 more secondary outcomes
Study Arms (2)
Sham inspiratory muscle training
SHAM COMPARATORCommercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance. The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks.
Active inspiratory muscle training
ACTIVE COMPARATORCommercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
Interventions
Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
Eligibility Criteria
You may qualify if:
- genetically-confirmed nemaline myopathy (mutations in one of the genes causing nemaline myopathy: TPM3, NEB, ACTA1, TPM2, TNNT1, KBTBD13, CFL2, KLHL40, KHLH41, LMOD3, MYPN, RYR1)
- informed consent from participant or legal representative
- age-range: between the age of 6-80 years
You may not qualify if:
- history of another condition that affects respiratory muscle strength or function (e.g. COPD)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Radboud university medical center
Nijmegen, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Baziel van Engelen, Prof. PhD
Promotor
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 15, 2018
First Posted
November 2, 2018
Study Start
October 10, 2018
Primary Completion
March 25, 2021
Study Completion
March 25, 2021
Last Updated
December 5, 2024
Record last verified: 2021-03